Haemostatic Agents Market Report

Global Haemostatic Agents Market Size

The Global Haemostatic Agents Market is projected to grow from USD 4.42 billion in 2025 to USD 4.66 billion in 2026 and reach USD 7.16 billion by 2034, registering a CAGR of 5.5% during the forecast period from 2026 to 2034.

MARKET DRIVERS

Hemostatic Agents refer to the class of substances usually used to promote hemostasis or stop bleeding. Haemostats are the technical term given to instruments used to reduce or halt bleeding during a surgical procedure.

Significant technological advancements in the field have increased hemostats' usage in surgical procedures in recent times. Common problems faced by hemostats include tissue contamination and ease of use. These have been addressed in the latest wave of innovations. The other significant factors affecting the Haemostatic Agents market include the rising prevalence of diseases and increasing awareness regarding the latest medical practices. Other drivers have increased health consciousness among consumers, the use of new inventions, and enhanced technologies.

Growth opportunities for the Haemostatic Agents Market lie in increasing awareness of the usage of hemostat instruments worldwide. The rise in the demand for surgical procedures to treat various diseases is likely to outshine the market's growth rate. Escalating expenditure on health care, especially in urban areas, boosts the growth rate of the hemostatic agents market. A growing tendency to improve the services in hospitals and promote the patient's well-being after treatment is ascribed to bolster the market's demand. The increasing geriatric population is also one of the factors propelling the growth rate of the hemostatic agents market. The rise in the number of people suffering from chronic diseases like cancer, ophthalmic injuries and replacement, diabetes, urological disorders, and many others where there is a particular need for surgical procedures propels the market's demand to the extent.

As for the market's restraints, the high costs and the unfavorable reimbursement policies are the major hurdles. It, along with the fact that people are unaware of the latest developments in developing and underdeveloped countries, restrains market growth.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Type Insights

Based on type, the thrombin-based hemostats segment held the major share of the market in 2023 and is estimated to grow at a healthy CAGR during the forecast period.On the other hand, the gelatin-based hemostats segment is predicted to have the highest CAGR in the coming years. Growing awareness of the benefits of these devices in the medical sector magnifies these segments' growth rate. Besides, initiative steps by the government are also accelerating the segment's growth rate. 

By Treatment Insights

Based on treatment, the cardiovascular segment accounted for a notable share of the worldwide market in 2023 and is expected to grow at a prominent CAGR during the forecast period owing to the growing patient population of cardiovascular diseases due to lifestyle changes and food habits.The General Surgery segment holds the second position in leading the shares.

By End User Insights

Based on end-user, the hospital segment is predicted to grow at a steady pace during the forecast period. The segmental growth is primarily driven by the increasing number of construction of hospitals and clinics with the latest technology.

REGIONAL ANALYSIS

The Haemostatic Agents Market was dominated by North America in 2023, with the region accounting for 36% of the overall market share. North America was followed next in line by Europe and Asia-Pacific. Asia-Pacific is expected to grow rapidly in the coming years, as is evident from the high CAGR value for the region. Another promising region for the market in Latin America, which is expected to show high growth rates in the coming years.

COMPETITIVE LANDSCAPE 

KEY MARKET PLAYERS

The Haemostatic Agents market is highly competitive with a large number of players. Haemostatic Agents Industry Key players dominating the market with their products and services are

• Ethicon,
• Pfizer,
• Baxter International,
• R. Bard,
• The Medicines Company,
• Anika Therapeutics,
• Advanced Medical Solutions,
• Integra LifeSciences,
• B Braun Melsungen,
• Gelita Medical,
• Equimedical,
• Vascular Solutions,
• Marine Polymer Technologies,
• Z-Medica.

GLOBAL HAEMOSTATIC AGENTS MARKET NEWS

• In June 2019, FDA approved VISTASEAL open and laparoscopic Dual applicators introduced Ethicon. These devices are used for next-generation technology and can be addressed for modern surgical bleeding. 

• In December 2018, Baxter International Inc. introduced hemostatic agents for ENT surgical procedures, an additional curved applicator for Floseal.

MARKET SEGMENTATION

This research report on the global hemostatic agents market has been segmented and sub-segmented based on the type, treatment, end-user, and region.

By Type

• Thrombin Based Haemostats          
• Gelatin Based Haemostats               
• Collagen Based Haemostats            
• Oxidized Regenerated Cellulose Based Haemostats
• Combination Haemostats 
• Fibrin Sealants       
• Others     

By Treatment

• Cardiovascular       
• General Surgery   
• Digestive Surgery 
• Neurosurgery        
• Others 

By End User

• Hospitals  
• Surgery Centres    
• Nursing Homes     
• Others   

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• The Middle East and Africa